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Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies
The paradigmatic view in cancer biology today is that neoplasia has a monoclonal origin [1] . Occasionally, however, clones with different aberrations are found within individual tumors [2] . Whether such a cytogenetic polyclonality represents a true polyclonal origin of the different clones or whether they share a submicroscopic primary change, indicating a monoclonal origin, is unknown. Recently, we reported that multicolor fluorescence in situ hybridization did not reveal any primary cryptic changes in fourteen investigated polyclonal hematologic malignancies [3] . We concluded that other methods to screen for common cryptic changes, such as genome-wide array-based comparative genomic hybridization (aCGH), perhaps could be fruitful.
We have performed aCGH on 6 polyclonal myeloid malignancies, comprising four acute myeloid leukemias and two myelodysplastic syndromes (Table 1) , using a 32K array set, consisting of 32,433 BAC clones covering 98% of the human genome, produced at the SWEGENE DNA microarray resource center (Lund University, Sweden). In all hybridizations, male reference genomic DNA was used (Promega, Madison, WI). Analyses of the microarray images were performed with GenePix Pro 4.0 software (Axon Instruments, Foster City, CA). To identify imbalances, the MATLAB toolbox CGH plotter was used, applying moving mean average of 3 clones and amplification/deletion limits of log2>0.2.
Mapping of gains or losses was based on identification as such by the CGH plotter and by visual inspection of the log2 ratios. All these analyses were performed in the BioArray Software Environment database [4] .
Apart from 15 copy number polymorphisms [5] , not expected to be involved in the leukemogenic process, no cryptic changes, linking the different clones together, were found in the aCGH analyses. However, it should be stressed that this does not necessary exclude the Abbreviations: M, male; F, female; AML, acute myeloid leukemia; rel, relapse; t-MDS, treatmentrelated myelodysplastic syndrome.
a The original karyotypes of cases 1 and 3 have previously been published in [3] .
b Normal karyotype at diagnosis.
